Contineum Therapeutics, Inc.(CTNM) - 2025 Q2 - Quarterly Results

Exhibit 99.1 CONTINEUM THERAPEUTICS REPORTS SECOND-QUARTER 2025 FINANCIAL RESULTS; UPDATES KEY CLINICAL DEVELOPMENT MILESTONES - Topline data from the PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple sclerosis (RRMS) is anticipated in the fourth quarter of 2025 - Initiation of a global Phase 2 proof-of-concept clinical trial of PIPE-791 in idiopathic pulmonary fibrosis (IPF) in the fourth quarter of 2025 - Cash runway projected to fund operations through 2027 SAN DIEGO – August ...